INTRODUCTION
(EUS-FNA) for pancreatic lesions is considered a minimally invasive diagnostic tool, and EUS-guided pancreatic injection of ethanol or other chemotherapeutic agents has been reported with few procedural complications. 7 Ethanol is the most commonly used ablative agent for focal pancreatic and hepatic lesions. [7] [8] [9] EUS-guided ethanol ablation has been recently proposed for the treatment of p-NETs. [10] [11] [12] [13] Levy et al. 12 reported that ultrasonography-guided ethanol ablation for insulinoma is technically feasible and safe, and symptomatic improvement was achieved in all eight patients (100%). However, these studies only included a small number of patients with functioning insulinomas. The aim of this pilot study was to investigate the safety, feasibility, and treatment response after EUS-guided ethanol injection for small p-NETs including nonfunctioning endocrine tumors.
MATERIALS AND METHODS

Data source and study population
Between February 2012 and February 2013, patients with suspicious p-NETs on imaging results and/or clinical features who were referred for differential diagnosis and management were enrolled in this study using specific inclusion and exclusion criteria. The diagnosis of p-NET was based on clinical and characteristic imaging findings, such as well-demarcated and hypervascular mass lesions in the pancreas (Fig. 1A) . The presence of a p-NET was further confirmed by p-NET cytology or histopathology from a core biopsy specimen. A diagnosis of insulinoma was suspected in patients with symptomatic fasting hypoglycemia, which includes: (1) symptoms and signs of hypoglycemia, (2) concomitant plasma glucose level of ≤45 mg/dL, and (3) reversibility of symptoms with glucose administration. A total of 11 patients were enrolled in the study, and they subsequently underwent EUS-guided fine-needle injection of 99% pure ethanol. The study was approved by the Institutional Review Board of the Asan Medical Center (Seoul, Korea), and written informed consent was obtained from all patients.
The inclusion criteria were as follows: (1) a p-NET <2 cm in diameter, (2) low suitability for surgery (multifocal location, American Society of Anesthesiologist physical status classification grade III or IV), (3) refusal of surgery, and (4) follow-up for >3 months after EUS-guided ethanol injection. The exclusion criteria were as follows: (1) refusal to participate in the study, (2) overt carcinomas, (3) bleeding tendency (prothrombin time >1.5 international normalized ratio or a platelet count <50,000/μL), (4) age <18 years, (5) pregnancy, and (6) active acute pancreatitis.
Procedures
EUS-guided intervention
All EUS procedures were performed after the patient was consciously sedated using midazolam and meperidine. To prevent acute pancreatitis and infection, a prophylactic antibiotic (ceftizoxime or ceftriaxone) and antiprotease prophylaxis (gabexate mesylate 300 mg in saline solution 500 mL, starting before the procedure and continuing for 24 hours) were intravenously administered.
The procedures were performed according to the following scheme:
(1)
Step 1: diagnostic contrast-enhanced harmonic EUS (CEH-EUS) with FNA was performed to confirm the neuroendocrine nature of the tumor. A curvilinear array echoendoscope (GF-UCT 240-AL 10; Olympus Medical System, Tokyo, Japan) was used to perform both CEH-EUS and FNA. The ultrasound processor was the Aloka Prosound Alpha 10 (Aloka Co., Ltd., Tokyo, Japan), which incorporates dedicated software for CEH-EUS. After a complete EUS examination of the pancreas in B-mode, the echoendoscope was switched to the CEH-EUS mode. SonoVue (Bracco, Milan, Italy) was used as a contrast agent. A bolus infusion of 2.5 mL of SonoVue into an antecubital vein was followed by injection of 10 mL of saline solution. EUS-FNA was performed using a 22-gauge needle (EchoTip Ultra or ProCore; Cook Endoscopy, Winston Salem, NC, USA).
(2)
Step 2: EUS-guided ethanol injection: the FNA needle was introduced into the tumor under real-time EUS. The optimal volume of ethanol (99%) injected into the tumor was determined according to the size of the tumor and calculated by computer estimation of areas on each axial image using EUS software permitting volume calculation (Fig. 1B) . Then, the needle was advanced into the tumor (Fig. 1C) , and the injections were repeated until the hyperechoic blush extended to the margin of the tumor (Fig. 1D) . At the end of ablation, EUS revealed an echogenic cloud in the mass. All patients were closely monitored for possible adverse events, including abdominal pain, bleeding, and infection, while maintaining a 24-hour restriction on food. Patients were discharged 2 days after the procedure if no adverse events developed.
Follow-up protocol
The study profile is outlined in Fig. 2 . After discharge, patients were followed up every 3 months on an outpatient basis for the first 2 years. The first follow-up contrast-enhanced computed tomography (CECT) was performed at 3 months after the procedure. At 3 months after the first CECT, residual viable tumor was considered present if enhanced areas were noted within the tumors on either the arterial phase or portal venous phase images. CEH-EUS was performed if there was uncertainty concerning the CECT findings regarding whether residual viable tumor was present. Further follow-up CECT was performed at 3-month intervals if an incomplete response was observed on the first follow-up CECT and at 6-month intervals if a complete response was observed on the first followup CECT. If a complete response was documented on two consecutive follow-up images, then a yearly follow-up was planned.
Main outcome measurements and definitions of clinical outcomes
The primary purpose of this study was to evaluate the technical feasibility and safety of EUS-guided ethanol injection in patients with p-NETs. The procedure was defined as feasible if the fine needle injection of ethanol inside the tumor was suc- cessful. An early adverse event was defined as any procedurerelated complication occurring within the first week. A late adverse event was defined as any complications arising at the site of the tumor within 3 months of the procedure. The secondary endpoint was the treatment response rate. Tumor viability was assessed using CECT and/or CEH-EUS after ablation. CECT/CEH-EUS disclosed a devascularized, hypodense area at the site of ablation (Fig. 1E) . CECT was reviewed by an expert radiologist, and an independent observer evaluated the microvasculature and parenchymal perfusion on CEH-EUS. Treatment responses were assessed according to enhanced residual tumor areas on CECT and/or CEH-EUS. Treatment responses were categorized as complete (the disappearance of any enhanced area within the tumors) or incomplete responses (persistence of enhanced tumor). Recurrence was defined as the development of enhancing tumor within the ablation zone and/or the appearance of a new lesion on followup CECT and/or CEH-EUS.
RESULTS
Patient characteristics
Eleven patients were enrolled during the study period. The patients and tumor characteristics are described in Table 1 . Six patients were women (55%), and the mean age of the patients was 52.5 years (range, 27 to 76). The mean size of the lesion was 12.2 mm (range, 8 to 19), and the most common location was within the head of the pancreas (n=6, 42.9%). The final diagnosis was based on histology and clinical signs as follows: 10 non-functioning neuroendocrine tumors and four insulinomas. Two patients had symptomatic hypoglycemia, and insulinoma was confirmed by biochemical analysis. Multiple tumors were identified in two patients with multiple endocrine neoplasia type 1 syndrome.
The operation could not be performed because of the location of the tumor requiring pancreaticoduodenectomy (n=3), patient refusal (n=4), and underlying comorbidities (n=4).
Feasibility and safety
All patients tolerated the EUS procedure. EUS-guided fine needle injection of ethanol was successfully performed in all 11 patients, who had 14 tumors in total, and a total of 18 treatment sessions were performed ( 
Treatment response
Ten patients with 13 tumors were followed up for a median of 370 days (range, 182 to 730) after EUS-guided ethanol fine needle injection, and one patient was lost to follow-up and excluded from the treatment analysis. Treatment responses are summarized in Table 3 . A single treatment session resulted in complete tumor ablation at the 3-month radiologic imaging of seven of 13 tumors (response rate, 53.8%). Multiple treatment sessions were performed for three tumors with enhanced residual viable tissue, which increased the number of tumors with a complete response to eight of 13 (response rate, 61.5%). None of these patients developed progressive disease during follow-up. The rate of local complete response was 61.5%. Patients who exhibited incomplete responses after multiple sessions of ethanol ablation received clinical follow-up. Two patients with insulinoma demonstrated the complete absence of hypoglycemic symptoms after treatment. Values are presented as mean±SD, mean±SD (range), or number (%). EUS-FNI, endoscopic ultrasonography-guided fine needle injection. 
DISCUSSION
There is growing interest and a need to use ethanol ablation to treat pancreatic lesions. This pilot study demonstrated that EUS-guided ethanol injection for p-NETs appears feasible as a potentially effective treatment with acceptable complication rates.
Ethanol has gained popularity as an ablative agent because it is inexpensive, is readily available, and has the potential to ablate tissue. The mechanism of ethanol ablation involves coagulation necrosis of the tumor as a result of cellular dehydration, protein denaturation, and vascular occlusion.
14, 15 Matthes et al. 16 reported a pilot study of EUS-guided fine needle injection of ethanol into the porcine pancreas, which resulted in localized tissue necrosis without complications. The major limitations of ethanol ablation are the possibility of late recurrence that would require retreatment, incomplete ablation, and the risk of progression during follow-up. It is important to note that complete treatment response in this study was assessed using follow-up enhanced imaging modality rather than histopathologic correlation. Injected ethanol may not always induce complete tumor ablation because of its inhomogeneous distribution within the tumor and its limited effects on extracapsular cancerous spread. 17 Physicians should consider the existing potential for residual tumor and progression. EUS-guided ethanol ablation should therefore be reserved for patients who refuse surgery or who are poor surgical candidates. Long-term follow-up study after ablation is needed before patients are considered cured of the disease.
Safety is an important issue in the potential clinical application of EUS-guided ethanol ablation. As with any ablative procedure, the main concern will be the risk of acute pancreatitis, which can result from the dispersion of ethanol outside the lesion and into the surrounding pancreatic parenchyma and/or the main pancreatic duct. A previous animal study that examined ablation of the porcine pancreas using ethanol injections reported that the area of inflammatory change associated with the injected ethanol is concentration-dependent, and local pancreatitis can occur. 9 In our study, three cases of mild pancreatitis occurred (27.2%). One patient developed pancreatic duct stricture as a late adverse event. The risk of developing pancreatitis appears to be associated with the total amount of ethanol injected into the tumor during the treatment session; specifically, all procedure-associated cases of pancreatitis occurred when >2 mL of ethanol were administered in a session. Different methods of increasing therapeutic efficacy, as well as avoiding the problems of pancreatitis, should be further explored.
It is difficult to satisfactorily measure the extent of ablation using CECT alone. CEH-EUS is increasingly used for the characterization of solid pancreatic masses. 18 Previous research demonstrated that CEH-EUS can be used both to detect p-NET and monitor necrotic areas caused by ethanol ablation. 19 In this study, we used CEH-EUS to facilitate the detection of p-NETs and postablation follow-up, and small hypovascular necrotic lesions were clearly observed because of substantial differences (e.g., the absence of contrast flow inside successful ablation sites and the surrounding enhanced normal pancreatic tissues).
Our study has several limitations. The number of patients was small, and the follow-up period may not have been sufficient to identify late tumor recurrence. Another weakness is the uncontrolled, retrospective study design. Nonetheless, our current pilot study is a useful forerunner of a large trial with a long-term follow-up period to fully elucidate the clinical benefits of EUS-guided ethanol ablation for p-NETs.
In conclusion, EUS-guided ethanol ablation is technically feasible and relatively safe, with a 61% treatment response rate in patients with p-NETs. Some improvements in the ablative agent and methodology are needed; however, this minimally invasive procedure could potentially be used to limit local tumor growth in patients who are unsuitable for surgery.
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